ASCO® 2023 Insights: "Updated Phase I Study Results of PHE885, a T-Charge Manufactured BCMA-Directed CAR T-Cell Therapy, for Pts With R/R MM"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Adam Sperling
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Adam Sperling
Login to view comments.
Click here to Login